Champions Oncology, Inc. revenue
Champions Oncology, Inc.'s revenue was $59.4m in fiscal 2026, up 4.4% on the year before. Since fiscal 2018 ($20.2m) it has grown at a compound 14.4% a year. Over the last twelve months it was $60.7m.
Revenue history
| Fiscal year | 2018Apr 2018 | 2019Apr 2019 | 2020Apr 2020 | 2021Apr 2021 | 2022Apr 2022 | 2023Apr 2023 | 2024Apr 2024 | 2025Apr 2025 | 2026Apr 2026 | LTMJul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20 | 27 | 32 | 41 | 49 | 54 | 50 | 57 | 59 | 61 |
| Growth on the year before | — | +33.7% | +18.7% | +27.8% | +19.7% | +9.7% | −6.9% | +13.5% | +4.4% | — |
| Gross profit | — | — | 15 | 20 | 25 | 24 | 21 | 29 | 29 | 30 |
| Gross margin | — | — | 47.1% | 47.7% | 51.9% | 45.2% | 41.4% | 50.1% | 48.0% | 49.8% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Pharmacology Services | $57.1M | 96.1% | ▲ 17.6% |
| Other | $1.5M | 2.6% | ▼ 58.5% |
| Translational Oncology Solutions TOS License Revenue | $764,000 | 1.3% | ▼ 83.7% |
From Champions Oncology, Inc.'s 10-K filed July 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Champions Oncology, Inc. | $60.7m | 6.7% | 4.8% |
| Precipio, Inc. | $60.8m | 29.5% | 43.6% |
| 908 Devices Inc. | $60.8m | 13.4% | 7.5% |
| Personalis, Inc. | $69.7m | -13.3% | 1.2% |
| Exagen Inc. | $71.1m | 20.8% | 10.3% |
| Burning Rock Biotech Ltd | $75.1m | 4.7% | — |
Compare with peers
- Precipio, Inc. revenue
- 908 Devices Inc. revenue
- Personalis, Inc. revenue
- Exagen Inc. revenue
- Burning Rock Biotech Ltd revenue
Head to head: CSBR vs PRPOCSBR vs MASSCSBR vs PSNL
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies